tecartus
kite pharma eu b.v. - autologous peripheral blood t cells cd4 and cd8 selected and cd3 and cd28 activated transduced with retroviral vector expressing anti-cd19 cd28/cd3-zeta chimeric antigen receptor and cultured (brexucabtagene autoleucel) - lymfom, mantelcelle - antineoplastiske midler - mantle cell lymphomatecartus is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl) after two or more lines of systemic therapy including a bruton’s tyrosine kinase (btk) inhibitor. acute lymphoblastic leukaemiatecartus is indicated for the treatment of adult patients 26 years of age and above with relapsed or refractory b-cell precursor acute lymphoblastic leukaemia (all).
epipen 0,3 mg/dosis injektionsv?ske, opl?sning
nordic prime aps - adrenalin - injektionsvæske, opløsning - 0,3 mg/dosis
adrenalin "nordic prime" 1 mg/ml injektionsvæske, opløsning
nordic prime aps - adrenalintartrat - injektionsvæske, opløsning - 1 mg/ml
adrenalin "epione medicine" 1 mg/ml injektionsvæske, opløsning
epione medicine aps - adrenalintartrat - injektionsvæske, opløsning - 1 mg/ml
carvykti
janssen-cilag international nv - ciltacabtagene autoleucel - multipelt myelom - carvykti is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.
jext 300 mikrogram injektionsvæske, opløsning i fyldt pen
2care4 aps - adrenalintartrat - injektionsvæske, opløsning i fyldt pen - 300 mikrogram
epipen jr. 0,15 mg/dosis injektionsvæske, opløsning
orifarm a/s - adrenalin - injektionsvæske, opløsning - 0,15 mg/dosis
columvi
roche registration gmbh - glofitamab - lymphoma, large b-cell, diffuse - antineoplastiske midler - columvi as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large b cell lymphoma (dlbcl), after two or more lines of systemic therapy.
tepkinly
abbvie deutschland gmbh & co. kg - epcoritamab - lymphoma, large b-cell, diffuse - antineoplastiske midler - tepkinly as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large b-cell lymphoma (dlbcl) after two or more lines of systemic therapy.
dimenhydrinat "karo pharma" 20 mg sugetabletter
karo pharma ab - dimenhydrinat - sugetabletter - 20 mg